Multiple Sclerosis (MS) Clinical Trials

Find Multiple Sclerosis (MS) Clinical Trials Near You

Clinnova-MS: a Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-Regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care (Switzerland)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as well as (ii) to investigate digital biomarkers allowing the continuous clinical monitoring of those patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18

• Participants are willing and able to comply with the protocol, including undergoing data and samples collection as well as study visits and examinations.

• Signed informed consent form

• In possession of a Healios+Me app compatible smartphone (iOS/Android)

• Corrected close visual acuity of ≥0.5

• Hand motor skills sufficient for using a smartphone

• Ability to follow the study procedures

• Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (clinically isolated syndrome, RRMS, SPMS, PPMS) AND early disease stages (\< 3 years) OR transitioning phase to progressive disease as evaluated based on Expanded Disability Status Scale (EDSS).

• Enrolled in the SMSC at University Hospital Basel

Locations
Other Locations
Switzerland
Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)
RECRUITING
Basel
Contact Information
Primary
Bebeka Cosandey (Clinnova:Scientific Project Lead), PhD
bebeka.cosandey@usb.ch
+41 79 961 26 31
Time Frame
Start Date: 2024-12-10
Estimated Completion Date: 2029-06
Participants
Target number of participants: 100
Treatments
MS patients
MS patients, recruited from the SMSC, are annually (optional 6-monthly) assessed and additionally, perform digital measurements with the Healios+Me app continuously after baseline up to 5 years as an optional follow-up study extension.
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Basel, Switzerland
Collaborators: Luxembourg Institute of Health, Research Center for Clinical Neuroimmunology and Neuroscience Basel

This content was sourced from clinicaltrials.gov